We live in close association with more microbial entities than we have human cells in our body. This complex network of microorganisms, our microbiome, is essential for the maintenance of our health, contributing to major functions involving digestive metabolism, competitive exclusion of environmental microbes, stimulation of the immune system and intestinal epithelium, and even gut-brain signaling. Thus, the balance of our gut ecosystem is essential for the maintenance of health and well-being.
(MaaT Microbiome Restoration Biotherapeutics)
Our MMRB platform has the objective to translate our science into biotherapeutics and is organized around two main pillars: two main pillars: our proprietary data collection and analysis platform (Gut Print) and our cGMP facility.
- 1014 prokaryotic cells
- High diversity of bacterial species (~200 per individual)
- Protective symbionts
Our microbiota is in permanent interaction with our human cells at mucosal interfaces. Intimate interactions provide the mutual benefit characteristics of a true symbiosis. For example, the immune system is permanently alert, ready to mount appropriate responses in the presence of pathogens while keeping a tolerance towards microbial symbionts. A dysregulated gut barrier and altered immune homeostasis leads to the loss of major functions and a pathological context with inflammatory conditions.
- Balanced dialogue
- Key functions: metabolism, competitive exclusion of pathogens, immune and epithelium stimulation
- Barrier effect
latrogenic stress : drugs, surgery, radiotherapy
Daily life stress : nutrition, birth, exposure to chemicals
Over only a few generations, humans have altered the trajectory of natural evolution of man-microbe symbiosis with fairly drastic changes in the environment and birth management, nutritional transition and increased exposure to chemical compounds. This has been associated with a rise in the incidence of immune-mediated chronic diseases that continues uncontrolled, predictions being that one third of the human population will be concerned by 2025. Clinical management of hospitalized patients will also often aggravate altered man-microbe symbiosis, leading to iatrogenic dysbiosis that can be considered a clinical condition in itself.
- Reduced richness and diversity
- Loss of symbionts / proliferation of pathobionts
- Barrier defect, uncontrolled local immune responses, systemic inflammation and oxidative stress.
Currently at the clinical stage, MaaT Pharma is one of most advanced companies in its sector, developing Gut Microbiome function restoration for cancer patients with very severe clinical conditions. Aligned for product launch, its unique cGMP platform – the first of its kind in Europe – has assisted the preparation of therapeutics that have proven their ability to rebuild symbiosis post-chemotherapy and that are being assessed for a potential impact on the survival of patients.
- Microbiota modulators: prebiotics, probiotics…
- Full ecosystem Microbiota Transfert
- MaaT Pharma Microbiome High Diversity Biotherapeutics
Our Integrative MMRB Platform is Driven by 2 Key Pillars: Gut Print, our Proprietary Data Collection & Analysis Platform as well as our cGMP Drug Production and Development platform
Gut Print produces big data to evaluate disease progression
Gut Print™ is our data science platform. It is a key pillar of our Research and Development platform to better elucidate the mechanism of dysbiosis and symbiosis. It uses the highest standards following GAMP5 guidelines and targeting FDA 21 CFR Part 11/ EudraLex Volume 4 Annex 11 and Annex 15 compliance. The main data entered into our unified database are: Meta-omics; Biological and Clinical data to allow the following functionalities:
- Novel ‘bio-target’ discovery
- Biotherapeutic characterization
- Mechanism of actions
- Proprietary Patient databases: keystone species, strains, variants, genes, metagenomic “species”, antibiotic-resistance genes, metabolic functions and proprietary models
- Big data sets (longitudinal and disease progression)
- Patient-specific microbiome screening, characterization and treatment
- Donor-specific microbiome screening, characterization and prognosis
- Treatment: Patient inclusion/exclusion criteria
- Dysbiosis correction
- Biomarker identification
- Donor selection
- Manufacturing QC analysis
- Species/Strain identification
We are keen to establish partnerships with Pharmaceutical companies in their development of drugs where the Microbiome plays a role
Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.
We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our Gut Print meta genomics platform.